RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Concert Pharmaceuticals Stock

Concert Pharmaceuticals ROCE 2024

Concert Pharmaceuticals ROCE

-0.69

Ticker

CNCE

ISIN

US2060221056

WKN

A1XEAC

In 2024, Concert Pharmaceuticals's return on capital employed (ROCE) was -0.69, a 0% increase from the 0 ROCE in the previous year.

Concert Pharmaceuticals Aktienanalyse

What does Concert Pharmaceuticals do?

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Concert Pharmaceuticals's Return on Capital Employed (ROCE)

Concert Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Concert Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Concert Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Concert Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Concert Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Concert Pharmaceuticals this year?

The ROCE of Concert Pharmaceuticals is -0.69 undefined this year.

How has the ROCE (Return on Capital Employed) of Concert Pharmaceuticals developed compared to the previous year?

The ROCE of Concert Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Concert Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Concert Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Concert Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Concert Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Concert Pharmaceuticals impact the company?

An increase in the ROCE of Concert Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Concert Pharmaceuticals affect the company?

A decrease in ROCE of Concert Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Concert Pharmaceuticals?

Some factors that can affect Concert Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Concert Pharmaceuticals so important for investors?

The ROCE of Concert Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Concert Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Concert Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Concert Pharmaceuticals pay?

Over the past 12 months, Concert Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Concert Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Concert Pharmaceuticals?

The current dividend yield of Concert Pharmaceuticals is .

When does Concert Pharmaceuticals pay dividends?

Concert Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Concert Pharmaceuticals?

Concert Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Concert Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Concert Pharmaceuticals located?

Concert Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Concert Pharmaceuticals from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Concert Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Concert Pharmaceuticals in the year 2023?

In the year 2023, Concert Pharmaceuticals distributed 0 USD as dividends.

In which currency does Concert Pharmaceuticals pay out the dividend?

The dividends of Concert Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Concert Pharmaceuticals

Our stock analysis for Concert Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Concert Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.